末期腎不全（ESRD）治療薬の世界市場レポート 2025年

末期腎不全（ESRD）治療薬の市場規模は今後数年で急成長が見込まれます。2029年にはCAGR15.7％で2,684億4,000万米ドルに成長します。予測期間の成長は、新たな治療法や薬剤の革新、ヘルスケア支出の増加、慢性腎臓病の世界的な負担増、個別化医療アプローチ、規制当局の支援、迅速な承認などに起因すると考えられます。予測期間における主な動向には、末期腎不全の発生率の増加、治療方法の進歩、精密医療への重点化の高まり、併用療法の開発、ヘルスケアにおける技術統合などがあります。

肥満と糖尿病の有病率の増加は、今後の末期腎不全（ESRD）治療薬市場の成長を促進すると予想されます。肥満は、健康上のリスクをもたらす脂肪の異常または過剰な蓄積を特徴とし、糖尿病は、膵臓が十分なインスリンを生成できない場合や、身体が生成したインスリンを効果的に使用できない場合に生じる慢性疾患です。腎臓病患者にとって、透析を通して体液や電解質のレベル、血圧、老廃物の排出を効果的に管理することは、全体的な健康と幸福を増進し、体重減少や血糖調節の改善につながる可能性があります。例えば、2022年3月、米国を拠点とし、肥満の研究と管理に焦点を当てた国や地域の団体を代表する組織であるWorld Obesityは、肥満の人の数が2025年までに8億9,200万人に増加し、2030年までに10億2,500万人に達すると予測しました。さらに、2023年2月、英国の公的医療制度であるNational Health Serviceは、英国における糖尿病患者数は2030年までに550万人に増加し、人口の9％近くが罹患する可能性があると推定しました。その結果、肥満と糖尿病の増加が末期腎不全（ESRD）治療薬市場を促進すると予想されます。

高血圧の有病率の上昇は、今後数年間、末期腎不全（ESRD）治療薬市場の成長を促進すると予測されています。高血圧症は、動脈壁に対する血液の力が長期的に一定して上昇することで定義される病状です。ESRD治療薬は、血圧をコントロールし、心血管リスクを低減し、疾患の進行を遅らせ、体液バランスと生活の質を改善することにより、高血圧を管理するために使用されます。例えば、2023年12月、オーストラリアの法定機関であるオーストラリア統計局は、2022年に人口の11.6％、約300万人が高血圧であったと報告しました。高血圧の割合は、男性、女性ともに同程度で、それぞれ11.7％、11.6％でした。高血圧の有病率は年齢とともに増加し、35～44歳の4.7％から45～54歳の12.4％へと約3倍に増加しました。この傾向は続き、75歳以上では半数近く（45.2％）が高血圧を報告しています。したがって、高血圧の有病率の増加が末期腎不全（ESRD）治療薬市場の拡大に拍車をかけています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の末期腎不全（ESRD）治療薬市場のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の末期腎不全（ESRD）治療薬市場：成長率分析
• 世界の末期腎不全（ESRD）治療薬市場の実績：規模と成長、2019～2024年
• 世界の末期腎不全（ESRD）治療薬市場の予測：規模と成長、2024～2029年、2034年
• 世界の末期腎不全（ESRD）治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の末期腎不全（ESRD）治療薬市場：製品タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• カルシウム受容体作動薬
• ビタミンD
• ステロール
• カリウム結合剤
• カルシウム系リン酸結合剤
• その他
• 世界の末期腎不全（ESRD）治療薬市場：適応症別、実績と予測、2019～2024年、2024～2029年、2034年
• 末期腎不全（ESRD）による副甲状腺機能亢進症
• 末期腎不全（ESRD）による高リン血症
• 末期腎不全（ESRD）による高カリウム血症
• 世界の末期腎不全（ESRD）治療薬市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• オンライン薬局
• 小売薬局
• 世界の末期腎不全（ESRD）治療薬市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• ホームケア
• 専門クリニック
• その他
• 世界の末期腎不全（ESRD）治療薬市場：カルシウム受容体作動薬のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• シナカルセト
• エテルカルセチド
• 世界の末期腎不全（ESRD）治療薬市場：ビタミンDのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• カルシトリオール
• ドキセルカルシフェロール
• パリカルシトール
• 世界の末期腎不全（ESRD）治療薬市場：ステロールのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• エルゴカルシフェロール
• コレカルシフェロール
• 世界の末期腎不全（ESRD）治療薬市場：カリウム結合剤のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ポリスチレンスルホン酸ナトリウム
• パチロマー
• ジルコニウムシクロケイ酸ナトリウム
• 世界の末期腎不全（ESRD）治療薬市場：カルシウム系リン酸結合剤のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 酢酸カルシウム
• 炭酸カルシウム
• 世界の末期腎不全（ESRD）治療薬市場：その他のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 鉄サプリメント
• 赤血球生成刺激剤

第7章 地域別・国別分析

• 世界の末期腎不全（ESRD）治療薬市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の末期腎不全（ESRD）治療薬市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 末期腎不全（ESRD）治療薬市場：競合情勢
• 末期腎不全（ESRD）治療薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • Astellas Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Fresenius SE & Co. KGaA
• Takeda Pharmaceutical Company Limited
• F. Hoffmann-La Roche Ltd.
• Kissei Pharmaceutical Co. Ltd.
• Baxter International Inc.
• AbbVie Inc.
• Amgen Inc.
• Akebia Drugs Inc.
• Bayer AG
• Bristol-Myers Squibb Company
• B. Braun SE
• Asahi Kasei Medical Co. Ltd.
• Nikkiso Co. Ltd.
• Abbott Laboratories
• Merck Co. & KGaA

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 末期腎不全（ESRD）治療薬市場2029年：新たな機会を提供する国
• 末期腎不全（ESRD）治療薬市場2029年：新たな機会を提供するセグメント
• 末期腎不全（ESRD）治療薬市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

End Stage Renal Disease (ESRD) drugs are medications employed in the treatment of a medical condition wherein a person's kidneys permanently cease to function, necessitating either a kidney transplant or a regular and long-term dialysis regimen to sustain life. These drugs play a crucial role in addressing and preventing secondary complications in individuals suffering from chronic renal disease (CKD).

The main categories of End Stage Renal Disease (ESRD) drugs include calcimimetics, vitamin D, sterols, potassium binders, calcium-based phosphate binders, and others. Calcimimetics are used to reduce parathyroid hormone (PTH) levels in kidney disease stage 5D, with their application dependent on serum calcium and phosphorus levels. Various indications for these drugs include ESRD-induced hyperparathyroidism, hyperphosphatemia, and hyperkalemia. End Stage Renal Disease drugs are distributed through hospital pharmacies, online pharmacies, and retail pharmacies, catering to usage in hospitals, homecare settings, specialty clinics, and other end-user environments.

The end stage renal disease (ESRD) drug market research report is one of a series of new reports from The Business Research Company that provides end stage renal disease (ESRD) drug market statistics, including end stage renal disease (ESRD) drug industry global market size, regional shares, competitors with an end stage renal disease (ESRD) drug market share, detailed end stage renal disease (ESRD) drug market segments, market trends and opportunities, and any further data you may need to thrive in the end stage renal disease (ESRD) drug industry. This end stage renal disease (ESRD) drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The end stage renal disease (ESRD) drug market size has grown rapidly in recent years. It will grow from $131.41 billion in 2024 to $149.88 billion in 2025 at a compound annual growth rate (CAGR) of 14.1%. The growth in the historic period can be attributed to increasing incidence of end stage renal disease, growing aging population, improved access to healthcare services, government initiatives and policies, increasing adoption of renal replacement therapies.

The end stage renal disease (ESRD) drug market size is expected to see rapid growth in the next few years. It will grow to $268.44 billion in 2029 at a compound annual growth rate (CAGR) of 15.7%. The growth in the forecast period can be attributed to emerging therapies and drug innovations, increasing healthcare expenditure, rising global burden of chronic kidney diseases, personalized medicine approaches, regulatory support, and expedited approvals. Major trends in the forecast period include increasing incidence of end stage renal disease, advancements in treatment modalities, growing emphasis on precision medicine, development of combination therapies, technological integration in healthcare.

The increasing prevalence of obesity and diabetes is anticipated to drive the growth of the end-stage renal disease (ESRD) drug market in the future. Obesity is characterized by an abnormal or excessive accumulation of fat that poses health risks, while diabetes is a chronic condition that arises when the pancreas fails to produce sufficient insulin or when the body cannot effectively use the insulin it produces. For individuals with renal disease, effectively managing fluid and electrolyte levels, blood pressure, and waste elimination through dialysis can enhance overall health and well-being, potentially leading to weight loss and better blood sugar regulation. For instance, in March 2022, World Obesity, a U.S.-based organization that represents national and regional associations focused on the study and management of obesity, projected that the number of obese individuals would increase to 892 million by 2025 and reach 1,025 million by 2030. Additionally, in February 2023, the National Health Service, the publicly funded healthcare system in the UK, estimated that the number of people with diabetes in the UK could rise to 5.5 million by 2030, affecting nearly 9% of the population. Consequently, the growing incidences of obesity and diabetes are expected to propel the market for end-stage renal disease (ESRD) drugs.

The rising prevalence of hypertension is projected to drive the growth of the end-stage renal disease (ESRD) drug market in the coming years. Hypertension is a medical condition defined by the long-term force of blood against artery walls that is consistently elevated. ESRD drugs are utilized to manage hypertension by controlling blood pressure, reducing cardiovascular risk, slowing disease progression, and improving fluid balance and quality of life. For example, in December 2023, the Australian Bureau of Statistics, a statutory authority in Australia, reported that 11.6% of the population, or approximately 3.0 million individuals, had hypertension in 2022. The rates of hypertension were similar for both males and females, at 11.7% and 11.6%, respectively. The prevalence of hypertension increased with age, nearly tripling from 4.7% in the 35-44 age group to 12.4% in the 45-54 age group. This trend continued, with nearly half (45.2%) of individuals aged 75 and older reporting hypertension. Therefore, the growing prevalence of hypertension is fueling the expansion of the end-stage renal disease (ESRD) drug market.

Innovative product development emerges as a prominent trend shaping the end-stage renal disease (ESRD) drug market landscape. Leading companies within this sector are prioritizing the development of innovative solutions to bolster their market positions. A notable instance occurred in April 2022 when GlaxoSmithKline Plc, a UK-based pharmaceutical and biotechnology firm, announced the acceptance of the New Drug Application (NDA) for daprodustat by the US Food and Drug Administration (FDA). Daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), is aimed at potentially treating chronic kidney disease anaemia (CKD). This product is founded on groundbreaking science that elucidated cellular oxygen sensing and adaptation, marking a milestone in novel therapeutic approaches within the ESRD drug market.

Prominent companies in the end-stage renal disease (ESRD) drug market are strategically focusing on securing product approvals, exemplified by Jardiance, to augment their market revenues. Jardiance, featuring empagliflozin, is tailored to aid individuals diagnosed with type 2 diabetes and reduce the risk of cardiovascular complications in those with type 2 diabetes experiencing heart failure or cardiovascular disease. A significant development occurred in September 2023 when Boehringer Ingelheim Pharmaceuticals Inc., a US-based pharmaceutical company, obtained FDA approval for Jardiance. This drug has received approval for various indications, including reducing the risk of end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease prone to progression. Additionally, it aims to diminish the risk of sustained decline in estimated glomerular filtration rate (eGFR) in adults suffering from heart failure. Notably, Jardiance operates as a sodium-glucose cotransporter 2 (SGLT2) inhibitor, with contraindications for patients with type 1 diabetes and those exhibiting an eGFR lower than 20 ml/min/1.73 m.

In August 2022, Gore & Associates, a materials science company based in the U.S., acquired InnAVasc Medical Inc. for an undisclosed sum. This acquisition enhances Gore's range of dialysis access solutions by integrating InnAVasc's innovative graft technology. The InnAVasc device is designed to offer safer, easier, and more reliable access for dialysis patients utilizing graft circuits, ultimately supporting better treatment outcomes. InnAVasc Medical Inc. specializes in medical technology aimed at improving care for patients with end-stage renal disease.

Major companies operating in the end stage renal disease (ESRD) drug market include Pfizer Inc., AstraZeneca plc, Sanofi SA, Astellas Pharma Inc., Novartis AG, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Kissei Pharmaceutical Co. Ltd., Baxter International Inc., AbbVie Inc., Amgen Inc., Akebia Drugs Inc., Bayer AG, Bristol-Myers Squibb Company, B. Braun SE, Asahi Kasei Medical Co. Ltd., Nikkiso Co. Ltd., Abbott Laboratories, Merck Co. & KGaA

North America was the largest region in the end stage renal disease (ESRD) drug market in 2024. The regions covered in the end stage renal disease (esrd) drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the end stage renal disease (esrd) drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The end-stage renal disease (ESRD) drug market consists of sales of cinacalcet hcl, diuretics, sevelamer, epoetin alfa, and over-the-counter drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

End Stage Renal Disease (ESRD) Drug Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on end stage renal disease (esrd) drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for end stage renal disease (esrd) drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The end stage renal disease (esrd) drug market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Calcimimetics; Vitamin D; Sterols; Potassium Binders; Calcium-Based Phosphate Binders; Other Products
• 2) By Indication: End Stage Renal Disease (ESRD) Induced Hyperparathyroidism; End Stage Renal Disease (ESRD) Induced Hyperphosphatemia; End Stage Renal Disease (ESRD) Induced Hyperkaliemia
• 3) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
• 4) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
• Subsegments:
• 1) By Calcimimetics: Cinacalcet; Etelcalcetide
• 2) By Vitamin D: Calcitriol; Doxercalciferol; Paricalcitol
• 3) By Sterols: Ergocalciferol; Cholecalciferol
• 4) By Potassium Binders: Sodium Polystyrene Sulfonate; Patiromer; Sodium Zirconium Cyclosilicate
• 5) By Calcium-Based Phosphate Binders: Calcium Acetate; Calcium Carbonate
• 6) By Other Products: Iron Supplements; Erythropoiesis-Stimulating Agents
• Companies Mentioned: Pfizer Inc.; AstraZeneca plc; Sanofi SA; Astellas Pharma Inc.; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. End Stage Renal Disease (ESRD) Drug Market Characteristics

3. End Stage Renal Disease (ESRD) Drug Market Trends And Strategies

4. End Stage Renal Disease (ESRD) Drug Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global End Stage Renal Disease (ESRD) Drug Growth Analysis And Strategic Analysis Framework

• 5.1. Global End Stage Renal Disease (ESRD) Drug PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global End Stage Renal Disease (ESRD) Drug Market Growth Rate Analysis
• 5.4. Global End Stage Renal Disease (ESRD) Drug Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global End Stage Renal Disease (ESRD) Drug Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global End Stage Renal Disease (ESRD) Drug Total Addressable Market (TAM)

6. End Stage Renal Disease (ESRD) Drug Market Segmentation

• 6.1. Global End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Calcimimetics
• Vitamin D
• Sterols
• Potassium Binders
• Calcium-Based Phosphate Binders
• Other Products
• 6.2. Global End Stage Renal Disease (ESRD) Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• End Stage Renal Disease (ESRD) Induced Hyperparathyroidism
• End Stage Renal Disease (ESRD) Induced Hyperphosphatemia
• End Stage Renal Disease (ESRD) Induced Hyperkaliemia
• 6.3. Global End Stage Renal Disease (ESRD) Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• 6.4. Global End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End Users
• 6.5. Global End Stage Renal Disease (ESRD) Drug Market, Sub-Segmentation Of Calcimimetics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cinacalcet
• Etelcalcetide
• 6.6. Global End Stage Renal Disease (ESRD) Drug Market, Sub-Segmentation Of Vitamin D, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Calcitriol
• Doxercalciferol
• Paricalcitol
• 6.7. Global End Stage Renal Disease (ESRD) Drug Market, Sub-Segmentation Of Sterols, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ergocalciferol
• Cholecalciferol
• 6.8. Global End Stage Renal Disease (ESRD) Drug Market, Sub-Segmentation Of Potassium Binders, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sodium Polystyrene Sulfonate
• Patiromer
• Sodium Zirconium Cyclosilicate
• 6.9. Global End Stage Renal Disease (ESRD) Drug Market, Sub-Segmentation Of Calcium-Based Phosphate Binders, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Calcium Acetate
• Calcium Carbonate
• 6.10. Global End Stage Renal Disease (ESRD) Drug Market, Sub-Segmentation Of Other Products, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Iron Supplements
• Erythropoiesis-Stimulating Agents

7. End Stage Renal Disease (ESRD) Drug Market Regional And Country Analysis

• 7.1. Global End Stage Renal Disease (ESRD) Drug Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global End Stage Renal Disease (ESRD) Drug Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific End Stage Renal Disease (ESRD) Drug Market

• 8.1. Asia-Pacific End Stage Renal Disease (ESRD) Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific End Stage Renal Disease (ESRD) Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific End Stage Renal Disease (ESRD) Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China End Stage Renal Disease (ESRD) Drug Market

• 9.1. China End Stage Renal Disease (ESRD) Drug Market Overview
• 9.2. China End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China End Stage Renal Disease (ESRD) Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China End Stage Renal Disease (ESRD) Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India End Stage Renal Disease (ESRD) Drug Market

• 10.1. India End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India End Stage Renal Disease (ESRD) Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India End Stage Renal Disease (ESRD) Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan End Stage Renal Disease (ESRD) Drug Market

• 11.1. Japan End Stage Renal Disease (ESRD) Drug Market Overview
• 11.2. Japan End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan End Stage Renal Disease (ESRD) Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan End Stage Renal Disease (ESRD) Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia End Stage Renal Disease (ESRD) Drug Market

• 12.1. Australia End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia End Stage Renal Disease (ESRD) Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia End Stage Renal Disease (ESRD) Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia End Stage Renal Disease (ESRD) Drug Market

• 13.1. Indonesia End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia End Stage Renal Disease (ESRD) Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia End Stage Renal Disease (ESRD) Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea End Stage Renal Disease (ESRD) Drug Market

• 14.1. South Korea End Stage Renal Disease (ESRD) Drug Market Overview
• 14.2. South Korea End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea End Stage Renal Disease (ESRD) Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea End Stage Renal Disease (ESRD) Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe End Stage Renal Disease (ESRD) Drug Market

• 15.1. Western Europe End Stage Renal Disease (ESRD) Drug Market Overview
• 15.2. Western Europe End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe End Stage Renal Disease (ESRD) Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe End Stage Renal Disease (ESRD) Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK End Stage Renal Disease (ESRD) Drug Market

• 16.1. UK End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK End Stage Renal Disease (ESRD) Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK End Stage Renal Disease (ESRD) Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany End Stage Renal Disease (ESRD) Drug Market

• 17.1. Germany End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany End Stage Renal Disease (ESRD) Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany End Stage Renal Disease (ESRD) Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France End Stage Renal Disease (ESRD) Drug Market

• 18.1. France End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France End Stage Renal Disease (ESRD) Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France End Stage Renal Disease (ESRD) Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy End Stage Renal Disease (ESRD) Drug Market

• 19.1. Italy End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy End Stage Renal Disease (ESRD) Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy End Stage Renal Disease (ESRD) Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain End Stage Renal Disease (ESRD) Drug Market

• 20.1. Spain End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain End Stage Renal Disease (ESRD) Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain End Stage Renal Disease (ESRD) Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe End Stage Renal Disease (ESRD) Drug Market

• 21.1. Eastern Europe End Stage Renal Disease (ESRD) Drug Market Overview
• 21.2. Eastern Europe End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe End Stage Renal Disease (ESRD) Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe End Stage Renal Disease (ESRD) Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia End Stage Renal Disease (ESRD) Drug Market

• 22.1. Russia End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia End Stage Renal Disease (ESRD) Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia End Stage Renal Disease (ESRD) Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America End Stage Renal Disease (ESRD) Drug Market

• 23.1. North America End Stage Renal Disease (ESRD) Drug Market Overview
• 23.2. North America End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America End Stage Renal Disease (ESRD) Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America End Stage Renal Disease (ESRD) Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA End Stage Renal Disease (ESRD) Drug Market

• 24.1. USA End Stage Renal Disease (ESRD) Drug Market Overview
• 24.2. USA End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA End Stage Renal Disease (ESRD) Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA End Stage Renal Disease (ESRD) Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada End Stage Renal Disease (ESRD) Drug Market

• 25.1. Canada End Stage Renal Disease (ESRD) Drug Market Overview
• 25.2. Canada End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada End Stage Renal Disease (ESRD) Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada End Stage Renal Disease (ESRD) Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America End Stage Renal Disease (ESRD) Drug Market

• 26.1. South America End Stage Renal Disease (ESRD) Drug Market Overview
• 26.2. South America End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America End Stage Renal Disease (ESRD) Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America End Stage Renal Disease (ESRD) Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil End Stage Renal Disease (ESRD) Drug Market

• 27.1. Brazil End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil End Stage Renal Disease (ESRD) Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil End Stage Renal Disease (ESRD) Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East End Stage Renal Disease (ESRD) Drug Market

• 28.1. Middle East End Stage Renal Disease (ESRD) Drug Market Overview
• 28.2. Middle East End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East End Stage Renal Disease (ESRD) Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East End Stage Renal Disease (ESRD) Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa End Stage Renal Disease (ESRD) Drug Market

• 29.1. Africa End Stage Renal Disease (ESRD) Drug Market Overview
• 29.2. Africa End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa End Stage Renal Disease (ESRD) Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa End Stage Renal Disease (ESRD) Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. End Stage Renal Disease (ESRD) Drug Market Competitive Landscape And Company Profiles

• 30.1. End Stage Renal Disease (ESRD) Drug Market Competitive Landscape
• 30.2. End Stage Renal Disease (ESRD) Drug Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Astellas Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. End Stage Renal Disease (ESRD) Drug Market Other Major And Innovative Companies

• 31.1. Fresenius SE & Co. KGaA
• 31.2. Takeda Pharmaceutical Company Limited
• 31.3. F. Hoffmann-La Roche Ltd.
• 31.4. Kissei Pharmaceutical Co. Ltd.
• 31.5. Baxter International Inc.
• 31.6. AbbVie Inc.
• 31.7. Amgen Inc.
• 31.8. Akebia Drugs Inc.
• 31.9. Bayer AG
• 31.10. Bristol-Myers Squibb Company
• 31.11. B. Braun SE
• 31.12. Asahi Kasei Medical Co. Ltd.
• 31.13. Nikkiso Co. Ltd.
• 31.14. Abbott Laboratories
• 31.15. Merck Co. & KGaA

32. Global End Stage Renal Disease (ESRD) Drug Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The End Stage Renal Disease (ESRD) Drug Market

34. Recent Developments In The End Stage Renal Disease (ESRD) Drug Market

35. End Stage Renal Disease (ESRD) Drug Market High Potential Countries, Segments and Strategies

• 35.1 End Stage Renal Disease (ESRD) Drug Market In 2029 - Countries Offering Most New Opportunities
• 35.2 End Stage Renal Disease (ESRD) Drug Market In 2029 - Segments Offering Most New Opportunities
• 35.3 End Stage Renal Disease (ESRD) Drug Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer